{"id":1068483,"date":"2024-03-10T03:13:29","date_gmt":"2024-03-10T07:13:29","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/acumen-pharmaceuticals-presents-sabirnetug-acu193-fluid-biomarker-and-target-engagement-analyses-from-phase-1-intercept-ad-study-in-early\/"},"modified":"2024-08-18T11:47:51","modified_gmt":"2024-08-18T15:47:51","slug":"acumen-pharmaceuticals-presents-sabirnetug-acu193-fluid-biomarker-and-target-engagement-analyses-from-phase-1-intercept-ad-study-in-early","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/acumen-pharmaceuticals-presents-sabirnetug-acu193-fluid-biomarker-and-target-engagement-analyses-from-phase-1-intercept-ad-study-in-early.php","title":{"rendered":"Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early&#8230;"},"content":{"rendered":"<p><![CDATA[- Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug\u2019s downstream pharmacological effects in the brain in early AD]]><\/p>\n<p>Read the original post:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/03\/08\/2843122\/0\/en\/Acumen-Pharmaceuticals-Presents-Sabirnetug-ACU193-Fluid-Biomarker-and-Target-Engagement-Analyses-from-Phase-1-INTERCEPT-AD-Study-in-Early-Alzheimer-s-at-the-AD-PD-2024-Annual-Meeti.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early...\">Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read the original post: Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early... <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/acumen-pharmaceuticals-presents-sabirnetug-acu193-fluid-biomarker-and-target-engagement-analyses-from-phase-1-intercept-ad-study-in-early.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068483","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068483"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068483"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068483\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}